Review anchor
Alpha-1B adrenergic receptor
SINGLE PROTEIN · Rattus norvegicus
As of 2026-09-13
Evidence Snapshot
Alpha-1B adrenergic receptor
CHEMBL315
SINGLE PROTEIN
Rattus norvegicus
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Alpha-1B adrenergic receptor as ChEMBL target CHEMBL315, mapped to UniProt P15823. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL315
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P15823
Alpha-1B adrenergic receptor
UniProt accession via ChEMBL component mapping
As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-13
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why Alpha-1B adrenergic receptor matters
Alpha-1B adrenergic receptor is reviewed as Alpha-1B adrenergic receptor (UniProt P15823); the current evidence base includes 135 approved drugs, 1424 compounds, and 109 assays, with lead potency reaching pChEMBL 10.0.
Protein context
Alpha-1B adrenergic receptor
Alpha-1B adrenergic receptor Sequence length is 515 aa.
Review this target as Alpha-1B adrenergic receptor, mapped to UniProt P15823. Sequence length is 515 aa.
Protein source · UniProt accession via ChEMBL component mapping
UniProt P15823
Protein
Disease context
Disease signal
Disease relevance is not yet populated for this evidence card.
This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target recordActivity base
Portfolio and assay base
ChEMBL currently tracks 135 approved drugs, 1424 compounds, and 109 assays for this target. The dominant activity type is KI. CHEMBL1259128 is the current potency anchor at pChEMBL 10.0.
Use CHEMBL1259128 as the tractability anchor when discussing potency (pChEMBL 10.0).
Activity source · ChEMBL 36 via Core Engine
135 approved
pChEMBL 10.0
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why Alpha-1B adrenergic receptor matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract behind UniProt P15823, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
1424
Total Compounds
109
Total Assays
135
Approved Drugs
IC50: 864.0, KI: 918.0, EC50: 19.0, KD: 121.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL1259128
|
10.0 | Ki | — |
|
|
No preferred name
CHEMBL2
|
10.0 | Ki | Approved |
|
|
No preferred name
CHEMBL27013
|
9.8 | Kd | — |
|
|
No preferred name
CHEMBL1259216
|
9.8 | Ki | — |
|
|
No preferred name
CHEMBL1259129
|
9.8 | Ki | — |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
SILODOSIN
CHEMBL24778
|
2008 |
|
|
ALFUZOSIN
CHEMBL709
|
2003 |
|
|
NAFTOPIDIL
CHEMBL142635
|
1999 |
|
|
SILDENAFIL
CHEMBL192
|
1998 |
|
|
QUETIAPINE
CHEMBL716
|
1997 |
|
|
TAMSULOSIN
CHEMBL836
|
1997 |
|
|
OLANZAPINE
CHEMBL715
|
1996 |
|
|
CARVEDILOL
CHEMBL723
|
1995 |
|
|
RISPERIDONE
CHEMBL85
|
1993 |
|
|
CISAPRIDE
CHEMBL1729
|
1993 |
|
|
SERTRALINE
CHEMBL809
|
1991 |
|
|
DAPIPRAZOLE
CHEMBL1201216
|
1990 |
|
|
DOXAZOSIN
CHEMBL707
|
1990 |
|
|
EBASTINE
CHEMBL305660
|
1990 |
|
|
CLOZAPINE
CHEMBL42
|
1989 |
|
|
CLOMIPRAMINE
CHEMBL415
|
1989 |
|
|
ASTEMIZOLE
CHEMBL296419
|
1988 |
|
|
TERAZOSIN
CHEMBL611
|
1987 |
|
|
OXYMETAZOLINE
CHEMBL762
|
1986 |
|
|
LABETALOL
CHEMBL429
|
1984 |
|
|
PENTAMIDINE
CHEMBL55
|
1984 |
|
|
GUANABENZ
CHEMBL420
|
1982 |
|
|
TRAZODONE
CHEMBL621
|
1981 |
|
|
VERAPAMIL
CHEMBL6966
|
1981 |
|
|
AMOXAPINE
CHEMBL1113
|
1980 |
|
|
MAPROTILINE
CHEMBL21731
|
1980 |
|
|
BROMOCRIPTINE
CHEMBL493
|
1978 |
|
|
DOBUTAMINE
CHEMBL926
|
1978 |
|
|
CLEMASTINE
CHEMBL1626
|
1977 |
|
|
PRAZOSIN HYDROCHLORIDE
CHEMBL1558
|
1976 |
|
|
LOPERAMIDE
CHEMBL841
|
1976 |
|
|
PRAZOSIN
CHEMBL2
|
1976 |
|
|
DROPERIDOL
CHEMBL1108
|
1970 |
|
|
DOXEPIN
CHEMBL1628227
|
1969 |
|
|
HALOPERIDOL
CHEMBL54
|
1967 |
|
|
EPINEPHRINE
CHEMBL679
|
1965 |
|
|
NORTRIPTYLINE
CHEMBL445
|
1964 |
|
|
THIORIDAZINE
CHEMBL479
|
1962 |
|
|
CYPROHEPTADINE
CHEMBL516
|
1961 |
|
|
AMITRIPTYLINE
CHEMBL629
|
1961 |
|
|
FLUPHENAZINE
CHEMBL726
|
1959 |
|
|
CHLORPROMAZINE
CHEMBL71
|
1957 |
|
|
PROCHLORPERAZINE
CHEMBL728
|
1956 |
|
|
PROMAZINE
CHEMBL564
|
1956 |
|
|
BENZTROPINE
CHEMBL1201203
|
1954 |
|
|
PHENTOLAMINE
CHEMBL597
|
1952 |
|
|
PROMETHAZINE
CHEMBL643
|
1951 |
|
|
ERGOTAMINE
CHEMBL442
|
1948 |
|
|
DIHYDROERGOTAMINE
CHEMBL1732
|
1946 |
|
|
MIANSERIN
CHEMBL6437
|
— |
Source Header